Literature DB >> 15183210

Terminal dyspnea and respiratory distress.

Margaret L Campbell1.   

Abstract

Dyspnea is a subjective experience that can be reported by the patient. Respiratory distress is an observable corollary, and represents the physical or emotional suffering that results from the experience of dyspnea. Recognizing and understanding this subjective phenomenon poses a challenge to intensive care unit (ICU) clinicians when caring for the patient who is dying in the ICU. Dyspnea and cognitive impairment are highly prevalent in the terminally ill ICU patient. A Respiratory Distress Observation Model may provide a theoretical foundation for the assessment of this phenomenon that is grounded in emotional and autonomic domains of neurologic function. Treatment of dyspnea and respiratory distress relies on nonpharmacologic interventions and opioids and sedatives. As with pain, the treatment of dyspnea and respiratory distress relies on close evaluation of the patient and treatment to satisfactory effect. Empirical evidence suggests that quality care with control of distressing symptoms does not hasten death. Withholding opioids or sedatives in the face of unrelieved dyspnea or respiratory distress has no moral foundation.

Entities:  

Mesh:

Year:  2004        PMID: 15183210     DOI: 10.1016/j.ccc.2004.03.015

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  6 in total

1.  The time-course of cortico-limbic neural responses to air hunger.

Authors:  Andrew P Binks; Karleyton C Evans; Jeffrey D Reed; Shakeeb H Moosavi; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2014-09-27       Impact factor: 1.931

2.  Guidelines for the withdrawal of life-sustaining measures.

Authors:  James Downar; Jesse W Delaney; Laura Hawryluck; Lisa Kenny
Journal:  Intensive Care Med       Date:  2016-04-08       Impact factor: 17.440

3.  Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates.

Authors:  David Hui; Margarita Morgado; Marieberta Vidal; Laura Withers; Quan Nguyen; Gary Chisholm; Clarence Finch; Eduardo Bruera
Journal:  J Palliat Med       Date:  2013-02-11       Impact factor: 2.947

4.  Interventions and decision-making at the end of life: the effect of establishing the terminal illness situation.

Authors:  C Campos-Calderón; R Montoya-Juárez; C Hueso-Montoro; E Hernández-López; F Ojeda-Virto; M P García-Caro
Journal:  BMC Palliat Care       Date:  2016-11-07       Impact factor: 3.234

Review 5.  Postoperative pain management in non-traumatic emergency general surgery: WSES-GAIS-SIAARTI-AAST guidelines.

Authors:  Federico Coccolini; Francesco Corradi; Massimo Sartelli; Raul Coimbra; Igor A Kryvoruchko; Ari Leppaniemi; Krstina Doklestic; Elena Bignami; Giandomenico Biancofiore; Miklosh Bala; Ceresoli Marco; Dimitris Damaskos; Walt L Biffl; Paola Fugazzola; Domenico Santonastaso; Vanni Agnoletti; Catia Sbarbaro; Mirco Nacoti; Timothy C Hardcastle; Diego Mariani; Belinda De Simone; Matti Tolonen; Chad Ball; Mauro Podda; Isidoro Di Carlo; Salomone Di Saverio; Pradeep Navsaria; Luigi Bonavina; Fikri Abu-Zidan; Kjetil Soreide; Gustavo P Fraga; Vanessa Henriques Carvalho; Sergio Faria Batista; Andreas Hecker; Alessandro Cucchetti; Giorgio Ercolani; Dario Tartaglia; Joseph M Galante; Imtiaz Wani; Hayato Kurihara; Edward Tan; Andrey Litvin; Rita Maria Melotti; Gabriele Sganga; Tamara Zoro; Alessandro Isirdi; Nicola De'Angelis; Dieter G Weber; Adrien M Hodonou; Richard tenBroek; Dario Parini; Jim Khan; Giovanni Sbrana; Carlo Coniglio; Antonino Giarratano; Angelo Gratarola; Claudia Zaghi; Oreste Romeo; Michael Kelly; Francesco Forfori; Massimo Chiarugi; Ernest E Moore; Fausto Catena; Manu L N G Malbrain
Journal:  World J Emerg Surg       Date:  2022-09-21       Impact factor: 8.165

6.  Anticipation of distress after discontinuation of mechanical ventilation in the ICU at the end of life.

Authors:  E J O Kompanje; B van der Hoven; J Bakker
Journal:  Intensive Care Med       Date:  2008-05-31       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.